Hydroxychloroquine
Conventional Synthetic Disease-Modifying Antirheumatic Drugs
Pharmacotherapy and Management Guidelines
Pharmacotherapeutic Options
Faced with ‘invisible illness,’ advocates vow to #MakeLupusVisible
May is Lupus Awareness Month, a time to raise awareness and educate the public on the physical, emotional and financial impact of lupus.
First-trimester hydroxychloroquine use adds no significant risk for birth defects
Hydroxychloroquine use for systemic lupus erythematosus or rheumatoid arthritis in the first trimester of pregnancy does not significantly increase the risk for major congenital malformations, according to data published in Rheumatology.
Stay within hydroxychloroquine ‘therapeutic threshold’ to reduce active lupus, flare risk
SAN DIEGO — Patients with lupus who maintained hydroxychloroquine blood levels of 750 ng/ml to 1,200 ng/ml exhibited 71% to 90% lower risk for high lupus disease activity, according to data presented at ACR Convergence 2023.
‘Now is the time for action’: ACR program seeks to overcome disparities in lupus care
SAN DIEGO — Improving hydroxychloroquine use and reducing glucocorticoid exposure are among the top priorities of the Healthy People with Lupus 2030 initiative, which aims to address care disparities, said a speaker at ACR Convergence 2023.
Hydroxychloroquine use predicts lower risk for fatty liver disease in rheumatoid arthritis
SAN DIEGO — Patients with rheumatoid arthritis who receive hydroxychloroquine demonstrate a lower risk for nonalcoholic fatty liver disease, according to data presented at ACR Convergence 2023.
Retina screening rate in patients receiving hydroxychloroquine ‘remains low’
Although the annual retinopathy screening rate in patients with lupus receiving hydroxychloroquine has increased from 3.5% in 2006 to 22.5% in 2019, more work is needed to raise awareness, according to data from a South Korean study.
VIDEO: New treatments on horizon for RA
In this video, Kathryn Dao, MD, associate professor in the department of internal medicine’s division of rheumatology at UT Southwestern Medical Center, discussed interesting new treatments on the horizon for RA, including new JAK inhibitors under development and a “scorpion venom toxin” with potential utility.